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ARTICLE

ATF4 is an oxidative stress–inducible,
prodeath transcription factor in neurons
in vitro and in vivo
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Oxidative stress is pathogenic in neurological diseases, including stroke. The identity of
oxidative stress–inducible transcription factors and their role in propagating the death
cascade are not well known. In an in vitro model of oxidative stress, the expression of the
bZip transcription factor activating transcription factor 4 (ATF4) was induced by glutathione depletion and localized to the promoter of a putative death gene in neurons. Germline
deletion of ATF4 resulted in a profound reduction in oxidative stress–induced gene expression and resistance to oxidative death. In neurons, ATF4 modulates an early, upstream event
in the death pathway, as resistance to oxidative death by ATF4 deletion was associated
with decreased consumption of the antioxidant glutathione. Forced expression of ATF4 was
sufficient to promote cell death and loss of glutathione. In ATF4ⴚ/ⴚ neurons, restoration of
ATF4 protein expression reinstated sensitivity to oxidative death. In addition, ATF4ⴚ/ⴚ mice
experienced significantly smaller infarcts and improved behavioral recovery as compared
with wild-type mice subjected to the same reductions in blood flow in a rodent model of
ischemic stroke. Collectively, these findings establish ATF4 as a redox-regulated, prodeath
transcriptional activator in the nervous system that propagates death responses to oxidative stress in vitro and to stroke in vivo.
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Free radicals and their reactive metabolites
(reactive oxygen species [ROS]) exist in neuronal cells and tissues at low but measurable
concentrations (1). These tolerable equilibrium concentrations are the result of a tightly
controlled balance between the rates of production and clearance, the latter being mediated by a team of antioxidants including enzymes
and nonenzymatic compounds such as the tripeptide glutathione.
Cells or tissues are in a stable oxidative
state if the rates of ROS production and scavenging capacity remain within a homeostatic
range. However, if this balance is disturbed,
The online version of this article contains supplemental material.
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either by an increase in ROS concentrations
or a decrease in antioxidant activities, the response may not be sufficient to keep the system at a level compatible with survival. In
such cases, oxidants can modify cellular targets, leading to cell dysfunction or death (2).
Indeed, oxidative stress has been implicated in
virtually all of the major acute and chronic
neurodegenerative diseases (3).
In many cells, including cortical neurons,
the expression of genes with antioxidative activity is precisely controlled by a synergistic
network of redox-sensing signaling cascades
(4, 5). Specifically, aberrant levels of oxidants can
trigger the transcriptional induction of antioxidative enzymes and other adaptive pathways (5).

Supplemental Material can be found at:
/content/suppl/2008/05/04/jem.20071460.DC1.html
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RESULTS
Amino acid depletion and thapsigargin treatment
induce ATF4 and protect embryonic cortical neurons
from oxidative stress–induced cell death
Amino acid depletion via the arginine-degrading enzyme
arginase is a well-characterized strategy for protecting neurons from oxidative stress–induced cell death (12, 17).
Studies in nonneural cells have shown that amino acid deprivation activates cell-survival pathways by activating the
bZip transcription factor ATF4 (11). We initiated our studies with the hypothesis that arginase is a multipotent inhibitor of apoptotic neuronal cell death by activating ATF4 and
its downstream gene targets. Because endoplasmic reticulum stress by thapsigargin is also associated with increased
ATF4 expression (18), we examined the corollary hypothesis that this agent could initiate tolerance to oxidative stress
in primary cortical neurons. As predicted, arginase and
thapsigargin led to nearly complete protection from neuronal cell death (Fig. 1, A and B) and to accumulation of
ATF4 protein (Fig. 1 C). Interestingly, we found that oxi1228

dative stress alone was sufficient to induce ATF4 protein
levels (Fig. 1 C).
Cortical neurons from ATF4ⴚ/ⴚ brains are resistant
to oxidative stress–induced cell death
To verify that the protection by arginase and thapsigargin requires ATF4, we cultured cortical neurons from brains of
embryonic ATF4⫺/⫺ mice (E15.5). Immunohistochemical
analysis (Fig. 2 A) using an antibody to microtubule-associated protein 2 (MAP2; which stains neural dendrites) showed
that basal viability and morphology of cell bodies and dendrites did not display any differences between ATF4+/+ and
ATF4⫺/⫺ neurons. We found that ATF4 mRNA was induced in ATF4+/+ neurons after oxidative stress and confirmed its absence in ATF4⫺/⫺ neurons (Fig. 2 B). We then
examined susceptibility to oxidative stress induced by the
glutamate analogue homocysteate (HCA) in ATF4+/+ and
ATF4⫺/⫺ cortical neurons (Fig. 2, C and D). Contrary to our
hypothesis, we found that ATF4⫺/⫺ neurons were significantly protected from oxidative stress–induced death. ATF4⫺/⫺
neurons demonstrated enhanced resistance, as monitored by
MTT reduction (Fig. 2 C) and live/dead staining (Fig. 2 D).
Moreover, in ATF4+/+ neurons, ATF4 induction by treatment with HCA was a result of induction at the translational
level (Fig. 2 E). We confirmed the nuclear accumulation of
ATF4 in ATF4+/+ neurons exposed to oxidative stress (Fig.
2 F). Higher nuclear ATF4 activity after oxidative stress was
demonstrated by showing higher promoter activity of an
ATF4 target gene, tribbles homologue 3 (TRB3), that has
been recently associated with cell death. TRB3 mRNA is
induced upon HCA treatment in an ATF4-dependent manner (Fig. 2 G). To characterize ATF4 binding on the promoter of TRB3, we generated a 2-kb fragment of the mouse
TRB3 promoter (Fig. 2 H). This fragment contains a 33-bp
element whose human analogue has been characterized as a
DNA binding region of ATF4. Transfection of both ATF4+/+
and ATF4⫺/⫺ neurons with the TRB3WT promoter construct, along with a mutant version lacking the binding element, revealed that this element plays an important but not
exclusive role in the induction of the TRB3 promoter after
oxidative stress. In the absence of ATF4, the TRB3 promoter
activity was not induced in response to oxidative stress.
Microarray analysis reveals that ATF4 regulates a subset
of genes that are induced in response to oxidative stress
In fibroblasts, previous studies (11) have established ATF4 as
an important prosurvival transcription factor in the context of
oxidative stress. Microarray analysis in that study (11) showed
that several ATF4-regulated genes in fibroblasts are involved
in amino acid import, glutathione biosynthesis, antioxidant
defense, and DNA repair. In contrast, in neurons, ATF4 has
classically been thought to act mainly as a transcriptional repressor. In this context, ATF4 has been hypothesized to negatively influence survival by repressing expression of genes
that are otherwise activated by prosurvival transcriptional activators such as cAMP response element binding protein.
ATF4 IS A PRODEATH PROTEIN IN NEURONS | Lange et al.
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The cellular response to oxidative stress is tightly controlled
by a family of stress-responsive transcription factors (2, 6).
Among these transcription factors, the activating transcription factor 4 (ATF4)/cAMP response element binding protein
2 may be a key player (7–9). ATF4 is expressed constitutively
only at low concentrations but becomes rapidly induced under
particular cell-stress conditions (10). ATF4 binds to the promoter regions of an array of different target genes, including many involved in amino acid metabolism and redox
control (11). In fibroblasts, ATF4 coordinates the response to
amino acid depletion, oxidative stress, and endoplasmic reticulum stress, and helps to balance redox homeostasis. Indeed,
ATF4-deficient fibroblasts have been shown to be prone to
death after a host of stresses, including oxidative stress and
amino acid deprivation (11).
Interestingly, amino acid deprivation has been previously
reported to be neuroprotective in an in vitro model of oxidative stress–induced cell death (12). This model employs immature cortical neurons and takes advantage of the absence of
glutamate receptors at this stage of development to avoid excitotoxicity. Instead, addition of glutamate analogues competitively inhibits uptake of cyst(e)ine, the rate-limiting
precursor for the tripeptide glutathione. The resulting decline in glutathione concentration is a primary event that
leads to neuronal cell death from oxidative stress (13–15), a
process that displays many features of apoptosis (14–16). This
glutathione depletion model facilitates the separation of biochemical events that mediate death from those that are a consequence of death, and it is highly relevant to pathological
conditions because an increase in cellular ROS production is
often observed in apoptotic processes triggered by diverse
stimuli associated with disease states. In this work, we define
a novel prodeath role for ATF4 in neurons in vitro in response to oxidative stress and in vivo in response to stroke, a
condition linked to oxidative stress.
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Figure 1. Amino acid depletion and thapsigargin treatment induce
ATF4 and protect embryonic cortical neurons from oxidative stress–
induced cell death. (A) Cortical neuronal cultures (1 d in vitro) were treated
with a vehicle control (shown as C), 10 mM of the glutamate analogue HCA,
1 μg/ml arginase, 1 μM thapsigargin, 1 μg/ml arginase and 10 mM HCA, or
10 mM HCA and 1 μM thapsigargin. 24 h later, cell viability was determined
using the MTT assay. The graph depicts mean (compared with control) ± SD
calculated from three separate experiments for each group (n = 25). *, P <
0.05 from HCA-treated cultures by the Kruskal-Wallis test followed by
JEM VOL. 205, May 12, 2008

Dunn’s multiple comparisons test. (B) Live/dead assay of cortical neuronal
cultures (2 d in vitro). Live cells were detected by uptake and trapping of
calcein-AM (green fluorescence). Dead cells failed to trap calcein but were
freely permeable to the highly charged DNA intercalating dye ethidium
homodimer (red fluorescence). Bar, 50 μm. (C) Treatment with 10 mM HCA
(shown as H) and 1 μg/ml arginase (shown as A) or 1 μM thapsigargin
(shown as T), alone or in combination with HCA, increases the expression of
ATF4 in cultured cortical neurons as compared with vehicle-treated control
(shown as C). Cells were harvested at the indicated time points, and nuclear
extracts were separated using gel electrophoresis and immunodetected
using an antibody against ATF4. YY1 was monitored as a loading control.
The immunoblot is a representative example of three experiments.
1229
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To begin to examine whether ATF4 functions primarily as a
repressor or activator in neurons and to determine the extent
to which these ATF4-regulated genes function similarly in
fibroblasts and neurons, we performed a global analysis of gene
expression using microarrays in ATF4+/+ and ATF4⫺/⫺
neurons (Fig. 3 A). More specifically, we assessed (a) the
physiological genomic effect of ATF4 knockout (comparing
ATF4⫺/⫺ with ATF4+/+ neurons), and (b) the effect of ATF4
knockout on the response to oxidative stress (comparing
ATF4⫺/⫺ with ATF4+/+ neurons after HCA treatment; Fig. 3
B and Table I). At the chosen statistical threshold (5% false
discovery rate), 136 probes were down-regulated in ATF4⫺/⫺
versus ATF4+/+ neurons, compared with 53 that were upregulated, suggesting a role for ATF4 as a transcriptional activator. Functional gene ontology categories overrepresented in
this list include mitochondrion, oxidoreductase activity, and
amino acid metabolism. Several of the down-regulated genes
have been shown to be positively regulated by ATF4, including the prodeath gene TRB3. Comparison of ATF4⫺/⫺ versus
ATF4+/+ neurons after oxidative stress with HCA treatment
suggested a fundamental role of ATF4 in modulating oxidative stress–induced gene expression. In fact, 119 probes are
dysregulated in response to oxidative stress in ATF4+/+ neurons, whereas only 3 change in ATF4⫺/⫺ neurons. Collectively, these findings suggest that ATF4 is a major upstream
regulator of oxidative stress–induced changes in gene expression. Additionally, for most genes in embryonic cortical
neurons, ATF4 functions as an activator and not a repressor.
Gene expression array data were obtained from ATF4⫺/⫺
fibroblasts that display a higher susceptibility to oxidative stress
(11). A significant overlap could be observed between the array
data from ATF4⫺/⫺ fibroblasts and neurons (Table S1, available
at http://www.jem.org/cgi/content/full/jem.20071460/DC1),
indicating that ATF4 regulates at least a major part of target
genes in a cell type–independent manner. These similarities do
not explain the observation that ATF4 is prosurvival in fibroblasts and prodeath in neurons, but they demonstrate the reliability in our analysis. In contrast, a subset of genes, including
the prodeath gene TRB3, were ATF4-regulated in neurons
but not in fibroblasts. Collectively, these findings provide some
understanding of the tissue-specific gene regulation mediated
by ATF4 that could account for the divergent phenotypes in
dividing fibroblasts versus postmitotic neurons.
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Figure 2. Cortical neurons from ATF4ⴚ/ⴚ brains are resistant to oxidative stress–induced cell death. (A) Immunocytochemistry of cultured ATF4+/+ and
ATF4⫺/⫺ cortical neurons. Cells were stained with an antibody against MAP2 (which stains neural dendrites; red) and counterstained with Hoechst (blue). Bar, 50 μm.
(B) Real-time PCR of ATF4 mRNA expression in ATF4+/+ and ATF4⫺/⫺ neurons in response to treatment with 10 mM HCA. The value obtained from the ATF4+/+
control was arbitrarily defined as 1. Mean ± SD was calculated from three separate experiments. Each data point was performed in duplicate. (C) Cortical neuronal cultures (1 d in vitro) prepared from brains from ATF4+/+ and ATF4⫺/⫺ embryos were treated with a vehicle control (shown as C) or 10 mM HCA. 24 h later, cell
viability was determined using the MTT assay. The graph depicts mean (compared with control) ± SD calculated from data from five separate experiments (n = 27
ATF4+/+ and 73 ATF4⫺/⫺). *, P < 0.05 from ATF4+/+ untreated cultures by the Kruskal-Wallis test followed by Dunn’s multiple comparisons test. The difference between treated and untreated ATF4⫺/⫺ neurons was not significant (n.s.). (D) Representative live/dead assay displaying untreated and HCA-treated ATF4+/+ and
ATF4⫺/⫺ neurons. Bar, 50 μm. (E) ATF4+/+ neurons were transfected with a reporter plasmid (pGL3 backbone) containing the mouse ATF4 5⬘UTR and AUG fused to
luciferase. Cortical neurons were cotransfected with a plasmid expressing Renilla to allow normalization for transfection efficiency. 24 h after transfection, neurons were treated with vehicle control (shown as C) or 10 mM HCA. Cells were harvested in luciferase assay buffer 12 h after the onset of treatment. Values were
1230
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ATF4 has a negative impact on neuronal glutathione
metabolism
The loss of glutathione is central to the in vitro model of
oxidative stress used in this study. This model has been successfully used to describe signaling pathways that prevent
cell death downstream of glutathione depletion. However,
in fibroblasts, ATF4 has been described as a positive regulator of glutathione metabolism (11). Therefore, we performed
glutathione measurements to determine whether ATF4 permits cell death in response to HCA by direct influence of the
neuronal glutathione metabolism or by acting downstream
of glutathione depletion. In untreated neurons, glutathione
concentrations in ATF4+/+ and ATF4⫺/⫺ neurons did not
differ (Fig. 6 A). As anticipated, HCA treatment caused a
progressive loss of glutathione in ATF4+/+ neurons. However, ATF4⫺/⫺ neurons displayed a markedly slower decline
in glutathione concentration. To rule out the possibility that
an increased rate of glutathione synthesis is responsible for
decreased sensitivity to cystine deprivation–induced glutathione depletion (20), we used buthionine sulfoximine (BSO)
to directly inhibit the rate-limiting enzyme of glutathione
synthesis, ␥-glutamylcysteine synthetase (␥-GCS; Fig. 6 B).
BSO resulted in cell death in ATF4+/+ neurons, whereas
ATF4⫺/⫺ neurons were essentially resistant (Fig. 6, C and D).
As expected from these results, ␥-GCS expression did not
differ between ATF4+/+ and ATF4⫺/⫺ neurons at the protein level and did not appear in the gene array (Fig. 6 E).
Similar to HCA, BSO treatment led to a decline in the concentration of glutathione in ATF4+/+ neurons, whereas
ATF4⫺/⫺ neurons displayed a distinctly slower reduction of
glutathione (Fig. 6 F). These findings are consistent with the
notion that the differences in reduction of glutathione after
HCA or BSO is not attributable to changes in synthesis. To
determine whether ATF4 directly regulates the neuronal
glutathione content, we measured glutathione in neurons
with forced expression of ATF4WT, ATF4⌬RK, and GFP
(Fig. 6 G). Consistent with the finding that forced expression
of ATF4WT can reduce neuronal viability, we found that
this viability reduction correlates with a reduction in the
neuronal glutathione content. Because cell death attributable to glutathione depletion can be completely blocked by
a whole host of classical antioxidants, we combined forced
expression of ATF4WT with butylated hydroxyanisol
(BHA) treatment (Fig. 6, H and I). BHA is a well characterized

calculated from three separate experiments and are given as the ratio of luciferase and Renilla activities (mean ± SD; n = 3). The value for treatment with vehicle
control was arbitrarily defined as 1. (F) Oxidative stress results in nuclear accumulation of ATF4 in cultured cortical neurons. 60 μg of nuclear extracts from cortical neurons treated with 10 mM HCA or vehicle control (shown as C) were separated using gel electrophoresis and immunodetected using an antibody against
ATF4. YY1 was monitored as a loading control. (G) Real-time PCR of TRB3 mRNA expression in ATF4+/+ and ATF4⫺/⫺ neurons in response to treatment with 10
mM HCA. The value obtained from the ATF4+/+ control was arbitrarily defined as 1. Mean ± SD was calculated from three separate experiments. Each data point
was performed in duplicate. (H) ATF4+/+ and ATF4⫺/⫺ neurons were transfected with a luciferase reporter plasmid (pGL3 backbone) containing a 2-kb fragment of
the mouse TRB3 promoter (TRB3WT), with a mutant version of this promoter lacking the 33-bp ATF4 binding site (TRB3⌬33bp) or with the empty vector (pGL3
basic). Cortical neurons were cotransfected with a plasmid expressing Renilla to allow normalization for transfection efficiency. 24 h after transfection, neurons
were treated with vehicle control (shown as C) or 10 mM HCA. Cells were harvested in luciferase assay buffer 12 h after the onset of treatment. Values are given
as the ratio of luciferase and Renilla activities (mean ± SD) and were calculated from three separate experiments. Each data point was performed in duplicate.
Values are given as the ratio of luciferase and Renilla activities (mean ± SD; n = 3). The value for empty pGL3 was arbitrarily defined as 1.
JEM VOL. 205, May 12, 2008
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Overexpression of ATF4 is sufficient to restore sensitivity
to glutathione depletion–induced cell death and is capable
of inducing cell death by itself
Because we used germline knockout animals (19) in this study,
we could not exclude the possibility that the decreased susceptibility to oxidative stress was a consequence of a compensatory effect distantly related to ATF4 deficiency. To address
this question, we used adenoviral overexpression of a mouse
ATF4WT construct. As a control, we used a dominantnegative ATF4 construct harboring a mutation in its DNA
binding domain (292RYRQKKR298 to 292GYLEAAA298). To
confirm the different DNA binding properties of these constructs, we analyzed the 33-bp binding region of the TRB3
promoter by gel-shift (Fig. 4 A) and chromatin immunoprecipitation studies (Fig. 4 B). In fact, only nuclear extracts
from cells overexpressing ATF4WT in combination with
WT oligonucleotide formed a band specific for ATF4. Consistently, only TRB3 promoter chromatin from cells overexpressing ATF4WT could be PCR amplified using primers
flanking the ATF4 binding site. Cotransfection of WT and
mutant ATF4 constructs with reporter constructs containing
the WT and the mutant binding site confirmed the activating
effect ATF4 has on transcription (Fig. 4 C).
To determine whether forced expression of ATF4 in
ATF4⫺/⫺ neuronal cultures can restore sensitivity to oxidative
stress and/or has an effect itself, we overexpressed both constructs
along with a GFP control in both ATF4+/+ and ATF4⫺/⫺ cortical neuronal cultures, followed by treatment with HCA (Fig.
5). We confirmed the efficient expression of both ATF4 constructs in cortical neurons by immunohistochemistry (Fig. 5 A)
and Western blotting (Fig. 5 B). Specifically, ⵑ50% of neurons
and a small number of glia are infected with the adenoviruses.
Infection with ATF4⌬RK was able to protect ATF4+/+ cortical neuronal cultures from HCA-induced toxicity (Fig. 5, C
and D), whereas infection with ATF4WT was capable of rendering ATF4⫺/⫺ neurons sensitive to HCA (Fig. 5, E and F).
Moreover, infection with ATF4WT itself significantly reduced
the viability in both WT and ATF4⫺/⫺ neurons. Combination
of forced expression of ATF4WT and treatment with HCA resulted in a higher loss of viability than infection with ATF4WT
alone, suggesting that at least one more pathway in addition to
ATF4 is involved in HCA toxicity. Collectively, these results
are consistent with the notion that ATF4 indeed plays a key
role in oxidative stress–mediated cell death.

Published May 5, 2008

Downloaded from on February 8, 2017
Figure 3. Gene expression array analysis of ATF4+/+ and ATF4ⴚ/ⴚ neurons before and after treatment with HCA. (A) Heatmap with cluster
dendrogram of the differentially expressed genes (log2 fold change vs. control) at a false discovery rate of 5%. Unsupervised clustering groups samples
by genotype and by treatment. Genes are in rows and samples are in columns. Column color coding is as follows: red, ATF4⫺/⫺ versus ATF4+/+ untreated
neurons; blue, HCA-treated ATF4⫺/⫺ versus untreated ATF4⫺/⫺ neurons; and green, HCA-treated ATF4+/+ versus untreated ATF4+/+ neurons. (B) The number of genes that are up- (red) and down-regulated (green). Shown are three different contrasts: ATF4⫺/⫺ versus ATF4+/+ untreated neurons, HCA-treated
ATF4+/+ versus untreated ATF4+/+ neurons, and HCA-treated ATF4⫺/⫺ versus untreated ATF4⫺/⫺ neurons. The complete list of differentially expressed
genes is available in Table S3 (available at http://www.jem.org/cgi/content/full/jem.20071460/DC1). ANOVA FDR, analysis of variance false discovery
rate; C, control.

antioxidant known to block HCA-induced cell death in
cortical neurons (6). In fact, in neurons overexpressing
ATF4WT, BHA significantly increased neuronal viability
and protected against the additional toxic effect of HCA
treatment. Finally, we measured production of ROS by us1232

ing the redox-sensitive probe 2⬘,7⬘-dichlorofluorescin
(DCF; Fig. S1, available at http://www.jem.org/cgi/content/
full/jem.20071460/DC1). Indeed, ATF4⫺/⫺ neurons displayed lower levels of ROS in response to HCA treatment
than ATF4+/+ neurons. These findings are consistent with
ATF4 IS A PRODEATH PROTEIN IN NEURONS | Lange et al.
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Table I.

Differentially expressed genes in ATF4-/- neurons versus ATF4+/+ neurons before and after HCA treatment

Downloaded from on February 8, 2017

From each of the three contrasts, the top 30 genes with the highest fold change were selected. Ratios are log2 transformed. Up-regulated genes (fold change > 0.2) are
highlighted in red, and down-regulated genes (fold change < ⫺0.2) are highlighted in green.

the notion that ATF4 positively influences ROS levels and
leads to a higher consumption of glutathione independent of
its synthesis.
ATF4ⴚ/ⴚ animals are less susceptible to ischemic brain damage
Oxidative stress is an established mediator of neuronal loss in
cerebral ischemia (21). It is generally accepted that glutathione acts as a major endogenous cerebral antioxidant in the
adult brain. In fact, depletion of intracellular antioxidants has
JEM VOL. 205, May 12, 2008

been associated with stroke pathology and repletion of antioxidants has reduced neuronal damage (22). Therefore, we
hypothesized that ATF4 deficiency might positively influence the antioxidant status in the adult brain and thereby improve the outcome after ischemia-reperfusion injury. To test
the hypothesis that ATF4 germline knockout animals have
less neuronal loss after stroke, we used a transient middle cerebral artery occlusion (MCAo) model for ischemia-reperfusion injury, as previously described (23).
1233
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Figure 4. ATF4 binds to a 33-bp binding element within the TRB3 promoter. (A) EMSA performed with 10 μg of dialyzed nuclear extracts
from HT22 cells transfected with ATF4WT, mutant ATF4 (ATF4⌬RK), or GFP, respectively. Extracts were incubated with a radioactively labeled WT
oligonucleotide containing the TRB3 promoter binding site or with a mutant oligonucleotide. Binding of ATF4WT to the TRB3WT promoter binding
site was confirmed by supershift analysis (arrow) performed with an antibody (Ab) directed against ATF4. (B) Overexpressed ATF4WT protein occupies
its putative binding site within the TRB3 promoter in HT22 cells, as shown by chromatin immunoprecipitation assay. HT22 cells were transfected with
ATF4WT, mutant ATF4 (ATF4⌬RK), or GFP. An anti-myc antibody was used to precipitate the proteins in nuclear extracts of cross-linked HT22 cells.
Coprecipitated DNA fragments were detected using PCR with a set of primers specific for the ATF4 binding site in the TRB3 promoter, yielding a
190-bp product. A representative example of three experiments is shown. (C) HT22 cells were transfected with the expression plasmids for ATF4WT,
mutant ATF4 (ATF4⌬RK), or GFP. The cells were cotransfected with either a luciferase reporter vector containing the 33-bp ATF4WT binding site (33 bp
WT), a reporter vector containing a mutant form of this binding site (33 bp MUT), or empty vector (pGL3 basic). In parallel, the transfection mix contained a plasmid expressing Renilla to allow normalization for transfection efficiency. The value for empty pGL3 cotransfected with GFP was arbitrarily defined as 1. Shown are ratios of luciferase and Renilla activities (mean ± SD for three independent experiments; each data point was
performed in duplicate).

First, we performed morphological studies to rule out that
germline ATF4 deficiency causes a fundamental abnormality
in the adult brain that would bias stroke outcome (19, 24–26).
Examining sagittal sections of brains from ATF4+/+ and
ATF4⫺/⫺animals (Fig. 7 A, top), we did not detect any significant structural differences in the cerebellum, hippocampus, or cortex. We then assessed the morphology of major
1234

cerebral blood vessels of the circle of Willis (Fig. 7 A, middle)
(23). Besides a higher degree of tortuosity in the MCA, no
major abnormalities were detected in the brains obtained from
ATF4⫺/⫺ mice. Finally, using immunofluorescent staining for
the endothelial-specific marker CD31/PECAM, we did not
observe significant differences in the density or morphology
of the microvessels (Fig. 7 A, bottom). In addition, important
ATF4 IS A PRODEATH PROTEIN IN NEURONS | Lange et al.
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Figure 5. Overexpression of ATF4WT restores sensitivity to oxidative stress and reduces neuronal viability itself. (A) Representative immunocytochemistry of ATF4+/+ and ATF4⫺/⫺ cortical neurons infected with the adenoviral constructs ATF4WT and ATF4⌬RK. Neurons were stained with antibodies against myc (green) and MAP2 (red), and were counterstained with Hoechst dye (blue). Bar, 50 μm. (B) Whole-cell extracts obtained from both
ATF4+/+ and ATF4⫺/⫺ neurons infected with GFP, ATF4WT, and ATF4⌬RK were separated using gel electrophoresis and immunodetected using an antibody
directed against the myc tag. Total eIF2␣ was monitored as a loading control. (C) ATF4+/+ cortical neurons were infected with GFP, ATF4WT, and ATF4⌬RK
adenoviruses at an MOI of 100. 24 h after infection, neurons were treated with vehicle control (shown as C) or 10 mM HCA. 24 h later, cell viability was
determined using the MTT assay. The graph depicts mean (compared with control) ± SD calculated from four separate experiments for each group (n =
45). P < 0.05 by the Kruskal-Wallis test followed by Dunn’s multiple comparisons test from untreated ATF4WT-overexpressing neurons (*) and from HCAtreated neurons overexpressing GFP (§). (D) Live/dead assay. Bar, 50 μm. (E) ATF4⫺/⫺ cortical neurons were infected with GFP, ATF4WT, and ATF4⌬RK adenoviruses at an MOI of 100. 24 h after infection, neurons were treated with vehicle control (shown as C) or 10 mM HCA. 24 h later, cell viability was
determined using the MTT assay. The graph depicts mean (compared with control) ± SD calculated from four separate experiments for each group (n =
28). P < 0.05 by the Kruskal-Wallis test followed by Dunn’s multiple comparisons test from untreated ATF4WT-overexpressing neurons (*) and from HCAtreated neurons overexpressing GFP (§). (F) Live/dead assay. Bar, 50 μm.

physiological parameters did not differ between ATF4+/+ and
ATF4⫺/⫺ animals (Fig. S2 and Table S2, available at http://
www.jem.org/cgi/content/full/jem.20071460/DC1).
JEM VOL. 205, May 12, 2008

The procedure used to occlude the MCA (occlusion time =
45 min) led to reproducible infarcts in WT animals involving
both the cerebral cortex and the striatum, with sparing of
1235
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Figure 6. ATF4 has a negative impact on the neuronal glutathione metabolism. (A) ATF4+/+ (䉬) and ATF4⫺/⫺ (䉱) cortical neurons were treated with
10 mM HCA. At the indicated time points, cells were trypsinized, washed, and pelleted. Reduced glutathione (GSH) was determined in the cell pellets using HPLC
electrochemical detection. Data are from three separate cultures, and each data point was measured in duplicate. Graph depicts mean ± SD. (B) Schematic
overview over cysteine uptake and glutathione synthesis and their inhibition. (C) ATF4+/+ and ATF4⫺/⫺ cortical neurons were treated with a vehicle control
(shown as C) or 200 μM BSO. 24 h later, cell viability was determined using the MTT assay. The graph depicts mean (compared with control) ± SD calculated
from five separate experiments for each group (n = 46 ATF4+/+ and 58 ATF4⫺/⫺). *, P < 0.05 from untreated ATF4+/+ cultures by the Kruskal-Wallis test followed
by Dunn’s multiple comparisons test. The difference between treated and untreated ATF4⫺/⫺ neurons was not significant (n.s.). (D) Live/dead assay displaying
untreated and BSO-treated ATF4+/+ and ATF4⫺/⫺ neurons. Bar, 50 μm. (E) Protein expression of ␥-GCS does not differ between ATF4+/+ and ATF4⫺/⫺ cortical
1236
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the hippocampus. However, a significantly smaller infarct
was observed when the procedure was performed in ATF4⫺/⫺
animals (Fig. 7, C and D). The smaller infarct area could be
observed in all sections of the brain. Thus, the higher resistance to ischemia-reperfusion injury was not limited to a specific brain area. In fact, the smaller infarct volume was
associated with a faster recovery in ATF4⫺/⫺ animals, as measured by a simple neurological score (Fig. 7 E). In addition,
two simple behavioral tests (Fig. 7, F and G) complemented
the morphological data. In consideration of the eye lens malformation regularly observed in ATF4⫺/⫺ animals (25), these
tests are not dependent on the visual sense. Consistent with
the morphological data, ATF4⫺/⫺ animals performed significantly better than the ATF4+/+ control group, suggesting that
ATF4 deficiency facilitates recovery after stroke.

ATF4 is a redox-regulated transcription factor
Classically, stress-mediated enhancement of ATF4 levels is
known to occur via enhanced efficiency of translation of
constant levels of ATF4 mRNA (29, 30). Consistent with
this model, we found an up-regulation of ATF4 mRNA
translational efficiency after glutathione depletion. However, we also observed an increase in ATF4 mRNA levels
after oxidative stress, thereby confirming a recent report
describing a role for transcriptional regulation in ATF4 induction by cell stress (31). The distinct increase in ATF4
protein levels in the nucleus of neurons undergoing oxidative stress corresponded to an ATF4-dependent induction
of a TRB3 promoter-luciferase reporter. Collectively, these
observations argue that oxidative stress–induced changes in
ATF4 mRNA levels and translational efficiency lead to increased ATF4 activity in neurons. Because ATF4 overexpression is sufficient to induce death, limiting the amount
of ATF4, at least under basal conditions, seems to be necessary for neuronal survival. Mechanisms that control and
limit basal ATF4 activity (32–34) appear to be important
determinants of neuronal fate. Although this low level of
ATF4 appears to be sufficient to regulate a host of genes, its
absence does not grossly influence neuronal morphology or
basal survival.
ATF4 has a direct impact on glutathione metabolism
Several converging lines of inquiry demonstrate a central
role for glutathione metabolism in degeneration and aging
in the nervous system. Our findings confirm the primary
role that glutathione can play in neuronal death. However,
the mechanisms by which a global depletion of glutathione
in neurons is transduced into apoptotic events remained
elusive. The data presented in this study favor a model in

neurons. Cytoplasmic extracts were separated using gel electrophoresis and immunodetected using an antibody against ␥-GCS. Total eIF2␣ was monitored
as a loading control. (F) ATF4+/+ (䉬) and ATF4⫺/⫺ (䊏) cortical neurons were treated with 200 μM BSO. At the indicated time points, cells were trypsinized,
washed, and pelleted. GSH was determined in the cell pellets using HPLC electrochemical detection. Data are from three separate cultures, and each data point
was measured in duplicate. Graph depicts mean ± SD. (G) ATF4+/+ cortical neurons were infected with GFP (䉬), ATF4WT (䊏), and ATF4⌬RK (䉱) adenoviruses
at an MOI of 100. At the indicated time points after infection, cells were trypsinized, washed, and pelleted. GSH was determined in the cell pellets using HPLC
electrochemical detection. The graph depicts mean ± SD calculated from three separate experiments for each group, and each data point was measured in
duplicate. The value obtained from noninfected neurons was arbitrarily defined as 100%. (H) ATF4+/+ cortical neurons were infected with GFP and ATF4WT adenoviruses at an MOI of 100. 24 h after infection, neurons were treated with vehicle control (shown as C), 10 mM HCA, 10 μM BHA, or a combination of both.
The graph depicts mean (compared with control) ± SD calculated from five separate experiments for each group (n = 29). *, P < 0.05 from untreated neurons
overexpressing ATF4WT by the Kruskal-Wallis test followed by Dunn’s multiple comparisons test. The difference between neurons overexpressing ATF4WT
treated with BHA alone and neurons overexpressing ATF4WT treated with both BHA and HCA was not significant (n.s.). (I) Live/dead assay. Bar, 50 μm.
JEM VOL. 205, May 12, 2008
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DISCUSSION
ATF4 is a prodeath transcription factor
Solid evidence supports the hypothesis that oxidative stress is
an initiator or propagator of neuronal dysfunction or death in
prevalent neurological diseases, including stroke, spinal cord
injury, Alzheimer’s disease, and Parkinson’s disease (3, 27).
These studies have led to the somewhat surprising conclusion
that oxidants can trigger neuronal death via highly regulated
signaling pathways and subsequent activation of prodeath transcription factors, leading to the controlled demise known as
apoptosis (28). The current study adds to our understanding of
the cellular transcription factors that regulate neuronal viability
and function after oxidative stress in primary cortical neurons.
Specifically, we show that the transcription factor ATF4 is induced by oxidative stress caused by depletion of the major antioxidant tripeptide, glutathione. We further demonstrate that
transgenic deletion of ATF4 renders neurons resistant to neuronal cell death. Prevention of cell death by germline knockout of ATF4 is associated with a preservation of glutathione
levels, the primary mediator of death in our oxidative stress
model. Consistent with ATF4’s role in regulating an early,
upstream aspect of the oxidative neuronal death pathway, we
found that ATF4 deficiency causes global down-regulation of
gene expression and blocks the up-regulation of many genes
that are induced by oxidative stress in WT neurons. Accordingly, forced expression of ATF4 was sufficient to promote
cell death and loss of glutathione. In addition, we demonstrate
that in ATF4⫺/⫺ neurons, restoration of ATF4 protein ex-

pression reinstated sensitivity to oxidative death. We establish
the relevance of protection by ATF4 deficiency by demonstrating that the ATF4 homozygous knockout is capable of
protecting the adult mouse brain from stroke-induced injury
and disability. Indeed, we show that ATF4⫺/⫺ animals recover
more easily and maintain proper motor function more efficiently. Although known to be a stress-responsive protein,
these results for the first time establish ATF4 as a redox-regulated protein that can function to lower the threshold for oxidative stress–induced death in neurons.
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Figure 7. Role of ATF4 in brain ischemia. (A, top) Sagittal sections of ATF4+/+ (left) and ATF4⫺/⫺ (right) brains stained with cresyl violet. Bar, 3,000 μm.
(A, middle) Ventral view of large cerebral blood vessels of representative ATF4+/+ (left) and ATF4⫺/⫺ (right) mice that were perfused with India ink.
Note the higher degree of tortuosity of the MCA in the brain from the ATF4⫺/⫺ mouse. Bar, 3,000 μm. (A, bottom) Representative microscopic views of
brain sections from ATF4+/+ and ATF4⫺/⫺ mice that were immunostained for the endothelial cell–specific marker CD31 (green). Bar, 100 μm. (B) Representative brain sections at 4 d after MCAo from ATF4+/+ (n = 5) and ATF4⫺/⫺ (n = 6) mice from rostral to caudal stained with cresyl violet to determine the
infarct area. Bar, 1,000 μm. (C) The infarct area in ATF4+/+ (䉬) and ATF4⫺/⫺ (䊏) brains was measured in 12 sequential sections taken from ATF4+/+ (n = 5)
and ATF4⫺/⫺ (n = 6) mice at rostral to caudal regular intervals. Graph depicts mean ± SD. (D) The infarct volume was assessed by adding the infarct volumes based on the infarct area in each section. Graph depicts mean ± SD. *, P < 0.0001 by the t test. (E) Scoring of neurological deficit was assessed at
different time points of recovery in ATF4+/+ (n = 5) and ATF4⫺/⫺ (n = 4) mice. Graph depicts mean ± SD. *, P < 0.05 by the Mann-Whitney test. (F) Inclined
plane test at different time points after stroke in ATF4+/+ (n = 5) and ATF4⫺/⫺ (n = 4) mice. The test measured the time a mouse managed to hold itself on
an inclined glass plate angled at 50° before sliding down. Graph depicts mean ± SD. *, P < 0.05 by the t test. (G) Hanging wire test at different time points
after stroke in ATF4+/+ (n = 5) and ATF4⫺/⫺ (n = 4) mice. The hanging wire test determined the time it took an animal to cross a distance of 45 cm on a
freely hanging narrow metal bar. Graph depicts mean ± SD. *, P < 0.05 by the t test.

which glutathione depletion causes an ATF4-dependent
up-regulation of a coordinated set of genes that orchestrate
the timely and irreversible demise of the cell. Part of the
orchestrated sequence of events downstream of ATF4 acti1238

vation includes the increased production of ROS and turnover of glutathione. Although our data clearly establish that
ATF4 induction does not influence glutathione synthesis,
we cannot determine whether the increased turnover of
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glutathione is primarily attributable to a change in a glutathione-degrading enzyme with a subsequent increase of ROS,
or a secondary consequence of ATF4-mediated ROS production. Increased ROS production would be expected to
decrease glutathione levels by enzyme-mediated consumption of the thiol tripeptide. Of note, many mitochondrial
genes that could facilitate production of deleterious ROS
during respiration are down-regulated in the ATF4⫺/⫺
neurons. Future studies will clarify whether ATF4 mediates
death primarily by altering glutathione turnover or by dialing up the production of free radicals.

The prodeath role of ATF4 might be context
and cell type specific
The data presented in this work are in support of a strong
prodeath role of ATF4. However, previous findings regarding the roles of ATF4 have yielded partly different results.
ATF4⫺/⫺ fibroblasts are impaired in expressing genes involved in amino acid import, glutathione biosynthesis, and
resistance to oxidative stress (11). Therefore, ATF4 was proposed to play a key role in rendering the cell more resistant
against the metabolic consequences of endoplasmic reticulum
oxidation. Therefore, we initially hypothesized that ATF4
induction by endoplasmic reticulum stress or amino acid depletion is the key event in the protection against oxidative
stress mediated by HCA treatment (Fig. 1). The finding that
ATF4 activation can be associated with protection from oxidative stress–induced cell death, although it clearly acts as a
prodeath transcription factor, points to a complex and context-specific role of ATF4 in the propagation of neuronal cell
death. However, both endoplasmic reticulum stress or amino
acid depletion initiate several different signaling events in
JEM VOL. 205, May 12, 2008

ATF4 is a prodeath transcription factor in vivo
We have established that ATF4 also plays an important prodeath role in an in vivo model of stroke. However, the use of
conventional ATF4⫺/⫺ animals poses a risk of bias on the
outcome in a complex paradigm such as stroke (53). Therefore, the results need to be interpreted with caution. We cannot rule out the possibility that ATF4 deficiency in all cell
types of the brain and the body has an impact on stroke outcome. However, no overt difference was observed when
comparing the brain morphology between WT and ATF4⫺/⫺
brains, including the vascular system. In addition, the smaller
infarct size in the ATF4⫺/⫺ mice could not be attributed to
changes in systemic physiological parameters, including body
temperature, or changes in cerebral blood flow under basal
conditions or after MCAo. However, an issue that was not
addressed in this study is whether the ATF4⫺/⫺ mice displayed an altered inflammatory response after ischemia that
could explain the smaller infarct size. Although a higher propensity to infections or other immune-related alterations has
not yet been observed in ATF4⫺/⫺ mice, we cannot rule out
the possibility that an altered inflammatory response (54) is
one reason for the smaller infarct volume in the ATF4⫺/⫺
mice. In summary, the strong correlation in the outcome between in vitro and in vivo studies lets us conclude that our
results, even when reviewed carefully, suggest an important
role for ATF4 in the induction of neuronal cell death. Thus,
ATF4 might be an important target for therapeutic intervention against stroke and other neurodegenerative diseases.
MATERIALS AND METHODS
Animals. All animal procedures were performed according to protocols
approved by the Institutional Animal Care and Use Committee of the Weill
Medical College of Cornell University. Germline ATF4⫺/⫺ mice have been
described previously (19). For the culture of mouse embryonic cortical
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ATF4 induces global transcriptional changes
ATF4 was originally described as a transcriptional repressor
(35, 36). However, our gene array data suggest that ATF4
acts at least in part as a transcriptional activator. This finding
is in line with several more recent publications that describe
the activating effect of ATF4 on several target genes, such as
heme oxygenase 1 (37, 38), stanniocalcin 2 (39), osteocalcin
(40), gadd153/CHOP (41), and TRB3 (42). Some of these
target genes have been shown to play an important role in
cell death and cell survival in the brain. Pharmacological induction of heme oxygenase 1 was demonstrated to protect
neurons from oxidative insults both in vitro and in vivo (43).
Indeed, heme oxygenase 1 is induced in WT neurons by oxidative stress; however, it was down-regulated in ATF4⫺/⫺
neurons. Likewise, stanniocalcin 2 is up-regulated in response
to oxidative stress in WT neurons but was down-regulated in
ATF4⫺/⫺ neurons. In a recent work (39), stanniocalcin 2 was
identified as an oxidative stress–responsive gene with cytoprotective properties. A prodeath ATF4 target gene, TRB3,
was strongly dependent on ATF4 and up-regulated in response to oxidative stress. TRB3’s role in neuronal apoptosis
was described first in a neuronal cell line (44) and has been
recently confirmed (42).

addition to ATF4 induction (2, 45). Which of these signaling
events are capable of preventing the deleterious consequences
of ATF4 activation requires further investigation. In general,
the similarity of data obtained from fibroblasts and from cortical neurons is limited. However, despite the opposite effects
on glutathione metabolism and cell survival, a comparison
between the array data from fibroblasts with our gene expression data indicates a highly significant overlap. Even
though the role of each of the many target genes of ATF4
warrant further investigation, the different metabolic demands of postmitotic neurons and actively dividing fibroblasts might help to explain the distinct role of ATF4 in
distinct cell types (46). Additionally, differently expressed dimerization partners of ATF4 might also significantly modify
ATF4’s function. Indeed, several different cancer cell lines
show an elevated level of ATF4 expression (10, 47–50).
Moreover, ATF4 is already known to have functions that are
limited to a specific cell type such as osteoblasts (40, 51, 52).
The precise characterization of these additional signaling
events warrants further investigation, and might help to explain why and how these signaling events are capable of preventing the deleterious consequences of ATF4 induction.
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neurons, embryos (15.5 days post conceptionem) were obtained from the
mating of ATF4 heterozygous mice.
Primary cortical neurons and cell culture. Primary neuronal cultures
were prepared from the cerebral cortices of mouse embryos, as described
previously (55), with minor modifications. The mouse hippocampal cell line
HT22 was maintained according to standard procedures (56). Transfection of
both cortical neurons and HT22 cells was performed using Lipofectamine
2000 (Invitrogen) according to the manufacturer’s instructions. Recombinant
arginase was provided by D. Ash (Temple University, Philadelphia, PA).
Genotyping. Genomic DNA for PCR was prepared using the DNeasy
genomic DNA isolation kit (QIAGEN). The WT alleles were detected using the primer 5⬘-AGCAAAACAAGACAGCAGCCACTA-3⬘. The ATF4⫺/⫺
alleles (neomycin) were detected using the primer 5⬘-ATATTGCTGAAGAGCTTGGCGGC-3⬘. As a common reverse primer, we used
5⬘-GTTTCTACAGCTTCCTCCTCCACTCTT-3⬘.

Plasmids. The expression plasmids for ATF4WT and dominant-negative
ATF4⌬RK (provided by J. Alam, Ochsner Foundation, New Orleans, LA)
(37), and the mouse ATF4 5⬘UTR luciferase construct (D. Ron, New York
University, New York, NY) have been previously described. The promoter
construct pTRB3 was generated by amplification of genomic mouse DNA
using the primers 5⬘-CTCACTCAGGTGCCTGTAGTGCTCG-3⬘ and 5⬘TCAGCAGAAGCAGCCAGAGGTGTAG-3⬘, followed by a second round
of PCR with the primers 5⬘-ACACTCGAGAGAGAAACAAATGTGTCATG-3⬘ and 5⬘-ACAAAGCTTCTAGAGAGCAAGGAAGAAAG-3⬘ before cloning into the vector pGL3basic (Promega). The mutant form lacking
the 33-bp ATF4 binding site was generated using a site-directed mutagenesis
kit (QuikChange; Stratagene). To generate the reporter plasmids with the
33-bp ATF4 binding sequence, the following oligonucleotides were annealed
and cloned into pGL3 basic: p33WT, 5⬘-TCGAGGCAGATTAGCTCAGGTTTACATCAGCCGGGCGGGGATCCA-3⬘ and 5⬘-AGCTTGGATCCCCGCCCGGCTGATGTAAACCTGAGCTAATCTGCC-3⬘;
and p33MUT (mutant form), 5⬘-TCGAGGCAGATTAGCTCAGTCTAAACCTATAGGGGCGGGGATCCA-3⬘ and 5⬘-AGCTTGGATCCCCGCCCCTATAGGTTTAGACTGAGCTAATCTGCC-3⬘. All sequences
were verified by automatic DNA sequencing.
Luciferase assay. Primary neurons and HT22 cells were transfected with
the respective reporter construct along with the pTK-Renilla control
(Promega). A dual luciferase assay (Promega) was performed using a bioluminometer (MDS Analytical Technologies), according to the manufacturer’s
instructions.
Adenoviruses. To generate the adenoviruses ATF4WT and ATF4⌬RK,
the expression cassettes of each construct were cloned into the shuttle vector
ad5 pVQ-K-NpA. The correct sequence was confirmed by automatic DNA
sequencing. Virus generation and amplification were performed by ViraQuest. Infection with adenoviruses was performed at a multiplicity of infection (MOI) of 100.
Gene array analysis. RNA quantity was assessed with a spectrophotometer
(Nanodrop; Thermo Fisher Scientific), and quality was assessed with nanochips (Bioanalyzer; Agilent Technologies). Total RNA was amplified,
labeled, and hybridized on arrays (MouseRef-8 Expression BeadChip; Illumina). Data analysis was performed using Bioconductor packages (available at
1240

DNA EMSA. Crude nuclear extracts were purified by dialysis using SlideA-Lyzer MINI Dialysis Units (Thermo Fisher Scientific). The following
oligonucleotide probes (Invitrogen) corresponding to the ATF4 binding site
of the TRB3 gene were used: TRB3WT, 5⬘-GATTAGCTCAGGTTTACATCAGCCGGGCGGGGA-3⬘; and TRB3MUT, 5⬘-GATTAGCTCAGTCTAAACCTATAGGGGCGGGGA-3⬘. The oligonucleotides were
annealed with complementary DNA and radiolabeled with ␥-[32P]ATP using T4 polynucleotide kinase. After incubation with nuclear extracts, the
DNA–protein complexes were resolved in 5% polyacrylamide gels, and the
signal was visualized using a PhosphorImager (Fujifilm).
Chromatin immunoprecipitation assay and PCR amplification. Formaldehyde cross-linking and chromatin immunoprecipitation
were performed as described previously (59). The cross-linked chromatin
suspension was sonicated using a Sonicator 3000 (Mosonix). Immunoprecipitation was performed with an anti-myc antibody. DNA–protein
cross-linking was reversed, followed by an overnight incubation at 65°C.
DNA was isolated by phenol/chloroform extraction and subjected to PCR
analysis using the primers 5⬘-GGTCACAGATGGTGCAATCC-3⬘ and
5⬘-AACTGAGCAGCTCTCGGAGTC-3⬘.
Glutathione determination using HPLC electrochemical detection
and ROS detection using DCF fluorescence. Concentrations of reduced
glutathione were measured using HPLC (PerkinElmer) equipped with an
eight-channel coulometric array detector (ESA, Inc.). Cells were lysed in 5%
(wt/vol) metaphosphoric acid and centrifuged at 10,000 g for 10 min to sediment protein. Cell-pellet precipitates were saved for protein determinations.
Glutathione concentrations of supernatant fractions were determined by injecting 5-μl aliquots onto an Ultrasphere 5 u, 4.6 × 250 mm, C18 column
(Beckman Coulter), and eluting with a mobile phase of 50 mM NaH2PO4,
0.05 mM octane sulfonic acid, 1.5% acetonitrile (pH 2.62) at a flow rate of
1 ml/min. Peak areas were analyzed using software from ESA, Inc. Intracellular
generation of ROS was determined by DCF. Cortical neurons were seeded in
96-well fluorescence plates. After the treatments indicated in the figures, the
cultures were incubated for 45 min with 1.25 μM DCF-H2. Cells were washed
with HBSS and read on a plate reader (Fluorometer; MDS Analytical Technologies) at 485-nm excitation and 530-nm emission wavelengths.
Cerebral ischemia. Transient focal cerebral ischemia was induced by
MCAo using the intraluminal filament method, as previously described (23).
Male mice were anesthetized. A small incision was performed in the skin
covering the scalp, and a fiber optic probe was glued to the parietal bone and
connected to a laser-Doppler flowmeter (Periflux System 5010; Perimed) for
continuous monitoring of cerebral blood flow. For MCAo, a heat-blunted
black monofilament surgical suture (6-0) was inserted into the exposed external carotid artery, advanced into the internal carotid artery, and wedged
into the circle of Willis to obstruct the origin of the MCA. The filament was
left in place for 45 min and withdrawn.
Physiological parameters. Animal physiology was assessed in ATF4+/+
and ATF4⫺/⫺ mice (n = 3 each). For this purpose, the left femoral artery was
cannulated using a polyethylene tube (PE-10; BD Biosciences) to record
mean arterial blood pressure. Blood samples were taken for chemical analysis
using a hand-held blood analyzer (iSTAT; Abbot Laboratories).
Quantification of infarct volume. Coronal brain sections were serially
cut in a cryostat (Leica) and stained with cresyl violet to identify viable tissue.
ATF4 IS A PRODEATH PROTEIN IN NEURONS | Lange et al.
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Cell viability/cell death assays. Cell viability was assessed by propidium
iodide uptake and retention of calcein (Invitrogen) using an inverted epifluorescence microscope (Axiovert 200M; Carl Zeiss, Inc.). MTT assay was
performed according to the manufacturer’s instructions (Promega). In brief,
absorbance was measured at 570 nm. From each data point, the reference
absorbance measured at 690 nm was subtracted. Finally, values were calculated as the percentage of untreated control cells.

http://www.bioconductor.org; reference 57). Raw data were log2 transformed and normalized using quantile normalization. Analysis of differential
expression was performed using a linear model fitting (LIMMA package; reference 58). The obtained p-values were corrected for multiple testing using
the false discovery rate method, and a threshold of 0.05 was applied. Microarray data have been deposited in the National Center for Biotechnology
Information Gene Expression Omnibus under accession no. GSE10470.
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To correct for the effect of edema, the infarcted area was determined indirectly by subtracting the area of the healthy tissue in the ipsilateral hemisphere from the area of the contralateral hemisphere on each section.
Infarction volume was calculated by integration of infarct areas measured in
20 equidistant brain sections that encompassed the whole lesion. Volumes
from all sections were summed to calculate total infarct volume.
Cerebral macrovascular morphology. To assess the morphology of major cerebral blood vessels of the circle of Willis, deeply anesthetized mice
were perfused transcardially with a prewarm (37°C) saline solution containing gelatin (20% wt/vol) and India ink (0.25% vol/vol).
Neurological evaluation. Neurological scores were assigned the following
values: 0, normal motor function; 1, flexion of torso and contralateral forelimb when the mouse was lifted by the tail; 2, circling to the contralateral
side when the mouse was held by the tail on a flat surface, but normal posture at rest; 3, leaning to the contralateral side at rest; and 4, no spontaneous
motor activity. The inclined plane test measured the time a mouse managed
to hold itself on an inclined glass plate angled at 50° before sliding down.
The hanging wire test determined the time it took an animal to cross a distance of 45 cm on a freely hanging narrow metal bar.
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Table S1. Comparison of the gene array data from this study with array data obtained from ATF4deficient fibroblasts
-/-

-/-

Atf4

Perk

Tm
Product/homology

GenBank

UT

Tm

UT

This
study

% of WT

SD

% of WT

SD

% of WT

SD

% of WT

SD
4

Translation, amino acid import, and metabolism
Asns

asparagine synthetase

U38940

x

14

1

24

4

67

11

58

EST

alanyl tRNA synthetase homolog

AI839392

x

17

1

42

5

67

7

91

5

Slc7a5

cationic amino acid transporter, y+ system

AB017189

x

18

1

40

9

40

18

55

13

AAAT

neutral amino acid transporter B

L42115

22

1

63

2

62

0

170

85

Mthfd2

methylenetatrahydrofolate dehydrogenase

J04627

x

22

5

36

7

87

21

68

8

Rpms7

phosphoserine aminotransferase homolog

AW122030

x

25

1

32

2

86

37

85

6

EST

L-3-phosphoserine phosphatase homolog

AI846545

27

1

52

10

63

3

63

5

PHAS-I; eIF4Ebp1

eukaryotic translation initiation regulator

U28656

x

27

2

46

1

59

15

64

0

Nars

asparaginyl-tRNA synthetase

AW125874

x

27

1

40

4

52

7

69

14

WRS

tryptophan-tRNA synthetase

X69656

31

2

44

19

10

3

43

13

meca39; Bcat1

branched chain aminotransferase 1

U42443

32

3

46

7

53

15

66

33

EST

threonyl-tRNA synthetase homolog

AI849620

32

6

45

7

58

24

74

11

EST

AI844089

33

0

55

9

50

3

68

11

Slc3a2

leucyl-tRNA synthetase homolog
4F2 antigen heavy chain, amino acid
transporter

X14309

35

2

63

14

86

23

82

8

EST

SYY-Tyrosyl tRNA synthetase homolog

AW122542

40

2

64

3

70

2

89

7

EST

isoleucine-tRNA synthetase homolog

AI848393

45

0

52

8

83

5

89

14

x

x

Redox or detoxification
EST

NADH-cytochrome B5 reductase homolog

AI839690

18

1

43

1

19

4

47

14

Cpo

coproporphyrinogen oxidase (hem6)

D16333

32

2

82

39

31

1

47

22

Ero1i-pending

ERO1 like, oxidoreductase

AA798624

36

1

63

16

57

6

77

24

EST

FKBP13/PDI homolog

AW122851

39

6

25

0

81

2

75

0

HO-1, Gmox1

heme oxygenase

X56824

x

45

2

65

5

67

3

69

5

C/EBPBeta

CCAAT/enhancer binding protein, Beta

M61007

x

15

4

31

2

29

7

51

17

Prx2

homeo box of paired rule

X52875

x

32

2

22

2

52

2

59

6

C/EBRGamma

GPE1-BP (C/EBPGamma)

AB012273

48

5

65

12

41

2

85

26

pentaxin related gene
galactoside-binding lectin; IgE binding
protein

X83601

7

1

31

14

10

1

32

10

X16834

15

1

18

11

238

120

207

148

Transcription

Secreted or transmembrane protein
ptx3
Lgals3, L-34
EST

coagulation factor XIIIa homolog

AI839918

19

1

46

8

50

12

71

1

X11Gamma

X11gamma protein, mint3, APBA3, Mint-3

AF070975

x

33

2

46

3

58

3

99

17

PMP22

Peripheral myelin protein

Z38110

x

37

3

40

1

102

52

52

10

Nid2, Ly111

Nidogen 2; entactin-2

AB017202

x

41

14

38

9

154

15

57

10

Signalling
IGFBP-2

insulin-like growth factor binding protein-2

X81580

7

0

9

1

13

7

12

2

Osmr

Oncostatin M receptor beta

AB015978

26

9

28

9

23

6

66

16

EST

EST, GTP-binding protein homolog

AA867773

36

6

60

0

88

16

100

10

OPG; Tnfrsf11b

osteoprotegerin, TGFbeta family

U94331

39

2

42

13

37

4

38

10

Arhj

Ras homolog gene family

AW121127

44

2

53

4

20

12

19

4

Wisp1

WNT1 inducible signaling pathway protein 1

AF100777

46

0

97

11

21

2

27

8

Grb10

growth factor receptor binding protein

U18996

47

5

50

13

70

8

71

12

Lon

Lon mitochondrial protease homolog

AI838015

PEDF, Serpinf11

serpin-f1 pigment epithelium-derived factor

AF036164

Gys

U53218

Clic4

muscle glycogen synthase
chloride intracellular channel 4
(mitochondrial)

MIBP-1

myc-intron-binding protein-1

Y15907

x

Miscellaneous

AI849533

x

x

2

1

104

109

27

3

195

174

10

1

20

3

29

1

37

1

43

0

50

0

44

3

56

4

46

1

70

13

62

3

46

10

47

0

69

8

24

33

56

12

An x indicates that the respective gene appears in both datasets as differentially expressed. 42 genes
were extracted in the fibroblast array, of which 18 overlap with this study. These are 43% of the 42 genes
of the fibroblast data resulting in a high level of significance at the hypergeometric test (P < 0.00001).

Table S2. Physiological data from ATF4+/+ and ATF4⫺/⫺ mice
WT
KO
before MCAo
pO2
mmHg
101.33 ± 3.51
101.33 ± 2.08
pCO2
mmHg
35.33 ± 0.58
33.67 ± 0.58
pH
7.44 ± 0.02
7.39 ± 0.02
HCO3⫺
mmol/l
22.61 ± 1.28
21.84 ± 0.42
Glucose
mg/dl
87.94 ± 3.78
90.38 ± 1.7
Lactate
mmol/l
1.20 ± 0.11
1.2 ± 0.07
mABP
73.95 ± 2.56
72.95 ± 2.94
o
mT
C
36.01 ± 0.19
35.61 ± 0.4
after MCAo
pO2
mmHg
97.67 ± 1.53
96.67 ± 0.58
pCO2
mmHg
32.33 ± 1.53
33.67 ± 1.15
pH
7.39 ± 0.02
7.38 ± 0.03
HCO3⫺
mmol/l
20.59 ± 0.66
20.86 ± 0.57
Glucose
mg/dl
86.58 ± 5.03
85.28 ± 1.05
Lactate
mmol/l
1.21 ± 0.05
1.19 ± 0.05
mABP
67.38 ± 2.71
66.31 ± 1.11
o
mT
C
35.49 ± 0.37
35.61 ± 0.41
Shown are the values for blood gases, pH, levels of bicarbonate, glucose, and lactate, and values for
mean arterial blood pressure and body temperature. Measurements were carried out 45 min before and
after MCAo for three animals each.

